Osteoarthritis is the most common form of arthritis, affecting millions of people worldwide. It happens when the protective cartilage that cushions your bones wears down over time. Osteoarthritis most commonly affects hands, knees, hips, and spine. Researchers and clinicians from BHI Therapeutic Sciences, USA and Blue Horizon International, Slovakia recently concluded cell-based therapy shows promising results in the regeneration of injured cartilage and serves as an anti-inflammatory for the affected joint.
The paper, “A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis” was recently published in the Journal of Clinical Medicine Research.
“Our study of 350 subjects with hip and knee osteoarthritis showed a significant improvement in pain levels and mobility at 3, 6, and 12 months compared to 7 days after autologous stromal vascular fraction (SVF) cell therapy,” said Brian Mehling, M.D., one of the authors of the study and the chief medical officer of BHI Therapeutic Sciences.
The study was approved by the Institutional Review Board of the Institute of Regenerative and Cellular Medicine (IRCM-2-17-137) and by the Ministry of Health of the Slovak Republic.
“The treatment demonstrated a strong safety profile with no severe adverse events or complications reported,” said Marina Manvelyan, Ph.D., clinical research scientist at BHI Therapeutic Sciences. “Interestingly, the results of the study show that SVF cell therapy was more effective in subjects with arthritis stage III compared to arthritis stages I, II, and IV,” she added.
The authors of the paper are Brian Mehling, Milan Hric, Adriana Salatkova, Robert Vetrak, Doreen Santora, Miriama Ovariova, Renata Mihalyova, and Marina Manvelyan.
BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.
The Journal of Clinical Medicine is an international, open access, and peer-reviewed journal that concentrates on general medical research and clinical practice. The journal aims to publish scientifically written, evidence-based articles from all disciplines of medical sciences and clinical practice, and nursing, preventive medicine, epidemiology, healthcare research, etc. All articles are rigorously peer-reviewed. The journal is indexed in PubMed and PubMed Central (PMC, US National Library of Medicine National Institutes of Health).
To read the study, visit bluehorizonstemcells.com.